Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by PfizerfiledCriticalPfizer
Priority to DO2003000667ApriorityCriticalpatent/DOP2003000667A/en
Publication of DOP2003000667ApublicationCriticalpatent/DOP2003000667A/en
Medicines That Contain Protein Lipid Enzymes And Other Medicines
(AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds
(AREA)
Abstract
La presente invención se refiere a una combinación de un ligadoalfa-2-delta y un inhibidor de PDEV para ser usado en teraoia, particularmente en el tratamiento curative, profiláctico o paliativo del dolor, particularmente el dolor neuropático. Los ligandos alfa-2-delta particularmente preferidos son gabapentina y pregabalina. Los inhibidores de PDEV particularmente preferidos son sildenafilo, vardenafilo y tadalafilo.The present invention relates to a combination of a ligadoalpha-2-delta and a PDEV inhibitor for use in teraoia, particularly in the curative, prophylactic or palliative treatment of pain, particularly neuropathic pain. Particularly preferred alpha-2-delta ligands are gabapentin and pregabalin. Particularly preferred PDEV inhibitors are sildenafil, vardenafil and tadalafil.
Compounds derived from resolviin; pharmaceutical composition; use of the composition; pharmaceutical kit; pharmaceutical combination; use of the compounds in the treatment and / or prevention of an ophthalmic condition.